AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

- 1. (Canceled)
- 2. (Previously amended) A compound represented by Formula (I):

$$R^3$$
 R^3
 R^2
 R^2
 R^2

or a pharmaceutically acceptable salt thereof, wherein

Ar is phenyl, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, or imidazolyl; or oxides thereof when Ar is a heteroaryl; Y is -COOH, or -C1-6alkyl(C1-4alkyl)n-COOH, wherein the -C1-6alkyl is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the (C1-4alkyl) substituents are optionally linked to form a C3-4cycloalkyl; wherein n is 0, 1, 2, 3 or 4;

R is H or -C₁-6alkyl;

R¹ is H, or -C₁-6alkyl, -C₃-6cycloalkyl, -C₁-6alkoxy, -C₂-6alkenyl, -C₃-6alkynyl, heteroaryl, or heterocycle group, optionally substituted with 1-3 independent haloC₁-6alkyl, -C₁-6alkyl, -C₁-6alkoxy, OH, amino, -(C₀-6alkyl)-SO_p-(C₁-6alkyl), nitro, CN, =N-O-C₁-6alkyl, -O-N=C₁-6alkyl, or halogen substituents, wherein p is 0, 1 or 2;

 R^2 is H, halogen,-CN, -NO₂, -C₁-6alkyl, -C₃-6cycloalkyl, -O- C₃-6cycloalkyl, O-C₁-6alkyl, O-C₃-6cycloalkyl-C₁-6alkyl(C₃-6cycloalkyl)(C₃-6cycloalkyl), -C₁-6alkoxy, phenyl, heteroaryl, heterocycle, amino, -C(O)-C₁-6alkyl, -C(O)-O-C₁-6alkyl, -C₁-6alkyl(=N-OH), -C(N=NOH)C₁-6alkyl, -C₀-6alkyl(oxy)C₁-6alkyl-phenyl, -SO_kNH(C₀-6alkyl), or -(C₀-6alkyl)-SO_k-(C₁-6alkyl), wherein the phenyl, heteroaryl or heterocycle is optionally substituted with halogen, -C₁-6alkyl, -C₁-6alkoxy, hydroxy,

amino, or -C(O)-O-C₁₋₆alkyl, and wherein the alkyl or cycloalkyl is optionally substituted with 1-6 independently selected halogens or -OH, and wherein k is 0, 1, or 2;

 R^3 is selected from H, halogen, CN, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, nitro, -C(O)-C₁₋₆alkyl, -C(O)-O-C₀₋₆alkyl, -SO_n'NH(C₀₋₆alkyl), or -(C₀₋₆alkyl)-SO_n'-(C₁₋₆alkyl), O-C₁₋₆alkyl, O-C₃₋₆cycloalkyl, wherein n' is 0, 1, or 2 and wherein the alkyl and cycloalkyl is optionally substituted with 1-6 independently selected halogen or OH.

3 to 10. (Canceled)

11. (Original) The compound according to claim 2, or a pharmaceutically acceptable salt, wherein

Ar is pyridyl, pyrimidyl, or oxide thereof.

12. (Original) The compound according to claim 11, or a pharmaceutically acceptable salt, wherein

 R^1 is $-C_1$ -6alkyl optionally substituted with 1-3 independent $-C_1$ -6alkyl, $-C_1$ -6alkoxy, OH, amino, $-(C_0$ -6alkyl) $-SO_p$ - $-(C_1$ -6alkyl), nitro, CN, =N-O- $-C_1$ -6alkyl, $-C_1$ -6alkyl, or halogen substituents.

13. (Original) The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R¹ is -C₃-6cycloalkyl optionally substituted with 1-3 independent -C₁-6alkyl, -C₁-6alkoxy, OH, amino, -(C₀-6alkyl)-SO_p-(C₁-6alkyl), nitro, CN, =N-O-C₁-6alkyl, -O-N=C₁-6alkyl, or halogen substituents.

- 14. (Original) The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen.
- 15. (Original) The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or .-C1-3alkyl or halogen.
- 16. (Original) The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R¹ is -C₃-6cycloalkyl optionally substituted with methyl or halo; and

R is hydrogen.

17. (Original) The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

 R^1 is cyclopropyl optionally substituted with methyl or halo; and R and R^2 are hydrogen or halogen; R^3 is hydrogen or halogen.

18. (Original) The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein

R and R3 are hydrogen,;

R¹ is -C₃-6cycloalkyl optionally substituted with methyl or halo, or -C₁-3alkyl optionally substituted with 1-3 halo; and Ar is phenyl.

19. (Canceled)

- 20. (Previously Amended) The compound which is 2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}cyclopropanecarboxylic acid;
- 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}-2-methylpropanoic acid;
- 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-2-methylpropanoic acid;
- 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-3-methylbutanoic acid;
- {3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}(hydroxy)acetic acid;
- 1-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(cis)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

```
5-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl}-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid;
```

- 1-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}cyclopropanecarboxylic acid;
- 1-cyano-3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-2,2-dimethylcyclopropanecarboxylic acid;
- (cis)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3'-bromo-5'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-3-methyl-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-2-methyl-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-carboxylic acid;
- 2-(trans)-{3'-[3-(morpholin-4-ylcarbonyl)-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3'-[4-oxo-3-({[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]amino}carbonyl)-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)-{3'-[3-({[2-(methylthio)ethyl]amino}carbonyl)-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2-(trans)- $\{3'-[3-(\{[2-(methylsulfonyl)ethyl]amino\}carbonyl)-4-oxo-1,8-naphthyridin-1(4$ *H* $)-yl]-1,1'-biphenyl-4-yl<math>\}$ cyclopropanecarboxylic acid;
- $2-(trans)-\{3'-[4-oxo-3-\{[(2,2,2-trifluoroethyl)amino]carbonyl\}-1,8-naphthyridin-1(4H)-yl]-1,8-naphth$
- 1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
- $2-(trans)-(5-\{3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-10-(trans)-(5-\{3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-10-(trans)-(5-\{3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-10-(trans)-(5-\{3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-10-(trans)-(t$
- yl]phenyl}thien-2-yl)cyclopropanecarboxylic acid;
- 2-(trans)-{3'-[3-{[(cyclopropylmethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4H)-yl]-
- 1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

- 2-(trans)-{3'-[3-{[(1-cyanocyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid; or 3-{3'-[3-[(isopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-3-methylbutanoic acid, or a pharmaceutically acceptable salt thereof.
 - 21. (Previously amended) A The compound which is
- $(+)-(trans)-2-\{3-fluoro-3'-[4-oxo-3-\{[(2,2,2-trifluoroethyl)amino]carbonyl\}-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl\} cyclopropanecarboxylic acid;$
- 1-({3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}methyl)cyclobutanecarboxylic acid;
- (trans)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2-methylcyclopropanecarboxylic acid;
- (trans)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}cyclopropanecarboxylic acid;
- 3-methyl-3- $\{3'-[4-\infty -3-\{[(2,2,2-trifluoroethyl)amino]carbonyl\}-1,8-naphthyridin-1(4H)-yl]$ butanoic acid;
- (trans)-2- $\{3'-[4-oxo-3-\{[(2,2,2-trifluoroethyl)amino]carbonyl\}-1,8-naphthyridin-1(4$ *H* $)-yl]biphenyl-2-yl<math>\}$ cyclopropanecarboxylic acid;
- (trans)-2-{3'-[4-oxo-3-{[(2,2,3,3,3-pentafluoropropyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (trans)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-1-fluorocyclopropanecarboxylic acid;
- (+)-(trans)-2-{3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (-)-(trans)-2-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (+)-(trans)-ethyl 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylate;
- (+)-(trans)-isopropyl 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylate;
- *tert*-butyl 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2,2-dimethylpropanoate;

- 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2,2-dimethylpropanoic acid;
- 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-3-yl}-2,2-dimethylpropanoic acid;
- 1-({3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-3-yl}methyl)cyclobutanecarboxylic acid;
- 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}-2,2-dimethylpropanoic acid;
- 1-({3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}methyl)cyclobutanecarboxylic acid;
- (+)-(trans)-2-{3'-[3-[(*tert*-butylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (+)-(trans)-2-{3'-[3-[(cyclobutylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}bicyclo[1.1.1]pentane-1-carboxylic acid;
- 4-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-4-hydroxypentanoic acid;
- $(trans)-2-{3'-[3-{[(\pm)-cis-(2-fluorocyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4$ *H* $)-yl]-(+)-biphenyl-4-yl}-cyclopropanecarboxylic acid;$
- (+)-(trans)-2-{3'-[3-{[(dicyclopropylmethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- 4-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2,2-dimethylbutanoic acid;
- (+)-(trans)-2-{3'-[3-{[(1-hydroxycyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (+)-(trans)-2-{3'-[4-oxo-3-{[(1-phenylcyclopropyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- 4-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-3,3-dimethylbutanoic acid;
- (+)-(trans)-2-{3'-[3-{[(1-cyclopropyl-1-methylethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

- 1-({3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}methyl)cyclobutanecarboxylic acid;
- (+)-(trans)-2-{3'-[3-{[(cyclopropylmethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (-)-(trans)-2-{3-fluoro-3'-[3-{[(1-hydroxycyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- (trans)-2- $\{3'-[4-oxo-3-\{[((\pm)-2,2,2-trifluoro-1-methylethyl)amino]carbonyl\}-1,8-naphthyridin-1(4H)-yl]-(+)-biphenyl-4-yl\}cyclopropanecarboxylic acid;$
- (+)-(trans)-2-{3'-[3-{[(1-methylcyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;
- 2,2-dimethyl-4- $\{3'-[4-oxo-3-\{[(2,2,2-trifluoroethyl)amino]carbonyl\}-1,8-naphthyridin-1(4$ *H* $)-yl]biphenyl-4-yl}butanoic acid;$
- 2,2-dimethyl-3-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}propanoic acid;
- (-)-(trans)-2-{3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid; or
- (+)-(trans)-2-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

U.S.S.N. CASE NO. MCO73YP PAGE NO. 9

22. (Previuosly amended) A pharmaceutical composition comprising

a therapeutically effective amount of the compound according to claim 2 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

- 23 to 24. (Canceled).
- 25. (Canceled).
- 26. (Canceled).
- 27 to 34. (Canceled)